tetrazoles

Summary

Top Publications

  1. ncbi Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes
    Hermann Haller
    Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
    N Engl J Med 364:907-17. 2011
  2. ncbi Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity
    Stephen C Benson
    Department of Biological Sciences, California State University, Hayward, USA
    Hypertension 43:993-1002. 2004
  3. ncbi Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
    Salim Yusuf
    McMaster Clinic, Room 252, Hamilton General Hospital, 237 Barton Street East, ON, L8L 2X2, Hamilton, Canada
    Lancet 362:777-81. 2003
  4. ncbi Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
    E J Lewis
    Department of Medicine, Rush-Presbyterian-St Luke's Medical Center, Chicago, IL 60612, USA
    N Engl J Med 345:851-60. 2001
  5. ncbi Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity
    Michael Schupp
    Center for Cardiovascular Research, Institut fur Pharmakologie und Toxikologie, Campus Charite Mitte, Charite Universitatsmedizin Berlin, Berlin, Germany
    Circulation 109:2054-7. 2004
  6. ncbi Ginkgo biloba extract enhances antiplatelet and antithrombotic effects of cilostazol without prolongation of bleeding time
    Keun Ho Ryu
    Pharmacology Team, Life Science R and D Center, SK Chemicals, Korea
    Thromb Res 124:328-34. 2009
  7. ncbi Irbesartan in patients with heart failure and preserved ejection fraction
    Barry M Massie
    University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco 94121, USA
    N Engl J Med 359:2456-67. 2008
  8. ncbi Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB
    Maristela Lika Onozato
    Division of Nephrology and Endocrinology, University of Tokyo, Tokyo, Japan
    Kidney Int 61:186-94. 2002
  9. ncbi Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients
    Yoshio Matsui
    Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, 3311 1 Yakushiji, Shimotsuke, Tochigi, Japan
    Hypertension 54:716-23. 2009
  10. ncbi The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
    H H Parving
    Steno Diabetes Center, Copenhagen, Denmark
    N Engl J Med 345:870-8. 2001

Detail Information

Publications294 found, 100 shown here

  1. ncbi Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes
    Hermann Haller
    Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany
    N Engl J Med 364:907-17. 2011
    ..We investigated whether treatment with an angiotensin-receptor blocker (ARB) would delay or prevent the occurrence of microalbuminuria in patients with type 2 diabetes and normoalbuminuria...
  2. ncbi Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity
    Stephen C Benson
    Department of Biological Sciences, California State University, Hayward, USA
    Hypertension 43:993-1002. 2004
    ....
  3. ncbi Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
    Salim Yusuf
    McMaster Clinic, Room 252, Hamilton General Hospital, 237 Barton Street East, ON, L8L 2X2, Hamilton, Canada
    Lancet 362:777-81. 2003
    ..We investigated the effect of addition of an angiotensin-receptor blocker to current treatments...
  4. ncbi Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
    E J Lewis
    Department of Medicine, Rush-Presbyterian-St Luke's Medical Center, Chicago, IL 60612, USA
    N Engl J Med 345:851-60. 2001
    ..CONCLUSIONS: The angiotensin-II-receptor blocker irbesartan is effective in protecting against the progression of nephropathy due to type 2 diabetes. This protection is independent of the reduction in blood pressure it causes...
  5. ncbi Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity
    Michael Schupp
    Center for Cardiovascular Research, Institut fur Pharmakologie und Toxikologie, Campus Charite Mitte, Charite Universitatsmedizin Berlin, Berlin, Germany
    Circulation 109:2054-7. 2004
    ..The peroxisome proliferator-activated receptor-gamma (PPARgamma) is the central regulator of insulin and glucose metabolism improving insulin sensitivity. We investigated the regulation of PPARgamma function by ARBs...
  6. ncbi Ginkgo biloba extract enhances antiplatelet and antithrombotic effects of cilostazol without prolongation of bleeding time
    Keun Ho Ryu
    Pharmacology Team, Life Science R and D Center, SK Chemicals, Korea
    Thromb Res 124:328-34. 2009
    ..With these studies, we suggest that combinative therapy of GB and cilostazol might offer enhanced anti-thrombotic efficacies without increasing side-effects...
  7. ncbi Irbesartan in patients with heart failure and preserved ejection fraction
    Barry M Massie
    University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco 94121, USA
    N Engl J Med 359:2456-67. 2008
    ..Therefore, we studied the effects of irbesartan in patients with this syndrome...
  8. ncbi Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: effects of ACEI and ARB
    Maristela Lika Onozato
    Division of Nephrology and Endocrinology, University of Tokyo, Tokyo, Japan
    Kidney Int 61:186-94. 2002
    ..We tested the hypothesis that Ang II subtype 1 (AT1) receptor activation enhances oxidative stress and nitrotyrosine deposition in the kidneys of rats with diabetes mellitus (DM)...
  9. ncbi Differential effects between a calcium channel blocker and a diuretic when used in combination with angiotensin II receptor blocker on central aortic pressure in hypertensive patients
    Yoshio Matsui
    Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University School of Medicine, 3311 1 Yakushiji, Shimotsuke, Tochigi, Japan
    Hypertension 54:716-23. 2009
    ..0 mg) and hydrochlorothiazide (12.5 mg), despite the lack of a significant difference in brachial systolic BP reduction between the 2 treatments...
  10. ncbi The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
    H H Parving
    Steno Diabetes Center, Copenhagen, Denmark
    N Engl J Med 345:870-8. 2001
    ..02). CONCLUSIONS: Irbesartan is renoprotective independently of its blood-pressure-lowering effect in patients with type 2 diabetes and microalbuminuria...
  11. pmc Rationale, study design, baseline characteristics and blood pressure at 16 weeks in the HONEST Study
    Ikuo Saito
    Keio University Health Center, Kanagawa, Japan
    Hypertens Res 36:177-82. 2013
    ..The HONEST Study is expected to provide evidence showing the relationship between baseline and on-treatment CBP and HBP levels (both first and second measurements) and CV events...
  12. pmc Angiotensin II AT1 receptor blockade prevents the hypothalamic corticotropin-releasing factor response to isolation stress
    Ines Armando
    Section on Pharmacology, Division of Intramural Research Programs, National Institute of Mental Health, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
    Brain Res 1142:92-9. 2007
    ..Inhibition of central AT(1) receptors limits the CRF response to stress and should be considered as a therapeutic tool to preserve homeostasis under chronic stress conditions...
  13. ncbi Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2)
    R Loch MacDonald
    St Michael s Hospital, University of Toronto, Toronto, ON, Canada
    Lancet Neurol 10:618-25. 2011
    ..We investigated whether clazosentan reduced vasospasm-related morbidity and all-cause mortality...
  14. ncbi Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study
    Srikanth Sola
    Division of Cardiology, Emory University School of Medicine, Atlanta, GA 30303, USA
    Circulation 111:343-8. 2005
    ..We evaluated the ability of irbesartan, an angiotensin receptor blocker, and lipoic acid, an antioxidant, to affect endothelial function and inflammation in patients with the metabolic syndrome...
  15. ncbi Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients W
    Young Hoon Jeong
    Division of Cardiology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea
    J Am Coll Cardiol 53:1101-9. 2009
    ..The purpose of this study was to determine the impact of adjunctive cilostazol in patients with high post-treatment platelet reactivity (HPPR) undergoing coronary stenting...
  16. ncbi A phosphodiesterase inhibitor, cilostazol, prevents the onset of silent brain infarction in Japanese subjects with Type II diabetes
    T Shinoda-Tagawa
    Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita City, Japan
    Diabetologia 45:188-94. 2002
    ..This study aimed to evaluate the effect of a phosphodiesterase inhibitor, cilostazol, on the prevention of silent brain infarction in diabetic patients without symptoms of vascular events...
  17. ncbi Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension
    William B White
    Division of Hypertension and Clinical Pharmacology, Calhoun Cardiology Center, University of Connecticut Health Center, 263 Farmington Ave, Farmington, CT 06030 3940, USA
    Hypertension 57:413-20. 2011
    ..Azilsartan medoxomil could provide higher rates of hypertension control within the ARB class...
  18. ncbi The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial
    Else Charlotte Sandset
    Department of Internal Medicine, Oslo University Hospital Ulleval, Oslo, Norway
    Lancet 377:741-50. 2011
    ..We aimed to examine whether careful blood-pressure lowering treatment with the angiotensin-receptor blocker candesartan is beneficial in patients with acute stroke and raised blood pressure...
  19. pmc Tetrazine ligation: fast bioconjugation based on inverse-electron-demand Diels-Alder reactivity
    Melissa L Blackman
    Brown Laboratories, Department of Chemistry and Biochemistry, University of Delaware, Newark, Delaware 19716, USA
    J Am Chem Soc 130:13518-9. 2008
    ..The rate of the ligation between trans-cyclooctene and 3,6-di-(2-pyridyl)-s-tetrazine is very rapid (k2 2000 M-1 s-1). This fast reactivity enables protein modification at low concentration...
  20. ncbi Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors
    Jurgen Janke
    Max Delbruck Center for Molecular Medicine, HELIOS Klinikum Berlin, Franz Volhard Clinic, Medical Faculty of the Charite, Humboldt University of Berlin, Berlin, Germany
    Diabetes 51:1699-707. 2002
    ..Because AGT secretion and Ang II generation are characteristic features of adipogenesis, we postulate a paracrine negative-feedback loop that inhibits further recruitment of preadipocytes by maturing adipocytes...
  21. ncbi Improved islet morphology after blockade of the renin- angiotensin system in the ZDF rat
    Christos Tikellis
    Danielle Alberti Memorial Centre for Diabetic Complications, Baker Medical Research Institute, Melbourne, Victoria, Australia
    Diabetes 53:989-97. 2004
    ..These findings provide a possible mechanism for the reduced incidence of new-onset diabetes that has been observed in clinical trials of RAS blockade...
  22. ncbi Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial
    Marcello Disertori
    Department of Cardiology, Santa Chiara Hospital, Trento, Italy
    Am Heart J 162:382-9. 2011
    ..In a consistent percentage of cases, AF recurrences are asymptomatic, thus making its clinical management difficult in relation to both therapeutic efficacy and thromboembolic risk...
  23. ncbi Antibiotic sensitization using biphenyl tetrazoles as potent inhibitors of Bacteroides fragilis metallo-beta-lactamase
    J H Toney
    Department of Biochemistry, Merck Research Laboratories, P O Box 2000, Rahway, NJ 07065 0900, USA
    Chem Biol 5:185-96. 1998
    ..Co-administration of metallo-beta-lactamase inhibitors to resistant bacteria is expected to restore the antibacterial activity of carbapenems...
  24. ncbi Pharmacokinetic interaction of fimasartan, a new angiotensin II receptor antagonist, with amlodipine in healthy volunteers
    SoJeong Yi
    Department of Pharmacology and Clinical Pharmacology, Seoul National University College of Medicine and Hospital, Jongno gu, Seoul, Republic of Korea
    J Cardiovasc Pharmacol 57:682-9. 2011
    ..The objective of this study was to investigate the effect of the coadministration of fimasartan and amlodipine on the steady-state pharmacokinetics of each drug...
  25. ncbi I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prosp
    Guillaume Bobrie
    Department of Hypertension, Hopital Europeen Georges Pompidou, Paris, France
    Clin Ther 34:1705-19. 2012
    ..Newer antihypertensive treatment combinations include fixed-dose combinations of an angiotensin receptor blocker and a calcium channel blocker...
  26. ncbi Real-life safety and effectiveness of amlodipine/valsartan combination in the treatment of hypertension
    Irina E Chazova
    Department of Systemic Hypertensions, Russian Cardiology Scientific Industrial Complex, Moscow, Russia
    Adv Ther 28:134-49. 2011
    ..The aim of our study was to evaluate the safety and effectiveness of the free combination of amlodipine/valsartan in patients with arterial hypertension in a real-life setting...
  27. ncbi Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II
    Yunzeng Zou
    Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, 1 8 1 Inohana, Chuo Ku, Chiba 260 8670, Japan
    Nat Cell Biol 6:499-506. 2004
    ..All of these events are inhibited by the AT1 receptor blocker candesartan. Thus, mechanical stress activates AT1 receptor independently of angiotensin II, and this activation can be inhibited by an inverse agonist of the AT1 receptor...
  28. ncbi RhoA activation in vascular smooth muscle cells from stroke-prone spontaneously hypertensive rats
    Nobuyuki Moriki
    First Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan
    Hypertens Res 27:263-70. 2004
    ..These results suggest that the possible mechanisms underlying RhoA activation in VSMC from SHRSP are autocrine/paracrine regulation by Ang II and/or cGKIalpha downregulation...
  29. pmc Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women: the inclusive trial
    Elizabeth O Ofili
    Morehouse School of Medicine, Atlanta, Georgia 30310, USA
    J Womens Health (Larchmt) 17:931-8. 2008
    ....
  30. ncbi Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial
    Atsushi Hirohata
    Sakakibara Heart Institute of Okayama, Okayama, Japan
    J Am Coll Cardiol 55:976-82. 2010
    ..The aim of this study was to evaluate the impact of olmesartan on progression of coronary atherosclerosis...
  31. ncbi Blockade of Angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation
    A Kurata
    Department of Metabolic Medicine, Graduate School of Medicine, Osaka University, Suita, Japan
    Kidney Int 70:1717-24. 2006
    ..Ang II signaling and subsequent oxidative stress in adipose tissue may be potential targets for the prevention of atherosclerotic cardiovascular disease in metabolic syndrome and also in metabolic syndrome-based CKD...
  32. ncbi A centrally acting, anxiolytic angiotensin II AT1 receptor antagonist prevents the isolation stress-induced decrease in cortical CRF1 receptor and benzodiazepine binding
    Juan M Saavedra
    Section on Pharmacology, National Institute of Mental Health, National Institutes of Health, DHHS, Bethesda, MD 20892, USA
    Neuropsychopharmacology 31:1123-34. 2006
    ..We propose that AT1 receptor antagonists can be considered as compounds with possible therapeutic anti-stress and anti-anxiety properties...
  33. ncbi High-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytes
    Vivek P Singh
    Division of Molecular Cardiology, Cardiovascular Research Institute, Texas A and M Health Science Center, College of Medicine, Temple, TX 76504, USA
    Am J Physiol Heart Circ Physiol 293:H939-48. 2007
    ..Significantly, NRVM synthesized and retained ANG II intracellularly, which redistributed to the nucleus under high-glucose conditions, suggesting a role for an intracrine mechanism in diabetic conditions...
  34. ncbi The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial
    Joel M Neutel
    Orange County Research Center, Tustin, CA 92780, USA
    J Clin Hypertens (Greenwich) 7:578-86. 2005
    ..Treatments were well tolerated. This irbesartan/HCTZ treatment regimen achieved SBP goals in more than 75% of patients uncontrolled on monotherapy...
  35. ncbi Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production
    Vivek P Singh
    Cardiovascular Research Institute, Texas A and M HSC, Temple, TX 76504, USA
    Am J Physiol Heart Circ Physiol 294:H1675-84. 2008
    ....
  36. ncbi Health care resources and costs for treating peripheral artery disease in a managed care population: results from analysis of administrative claims data
    Jay Margolis
    HealthCore, Inc, Wilmington, DE 19801 1366, USA
    J Manag Care Pharm 11:727-34. 2005
    ....
  37. ncbi Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial
    Toshio Ogihara
    Osaka University Graduate School of Medicine, Osaka, Japan
    Hypertension 51:393-8. 2008
    ..We disclosed that candesartan-based and amlodipine-based regimens produced no statistical differences in terms of the primary cardiovascular end point, whereas candesartan prevented new-onset diabetes more effectively than amlodipine...
  38. ncbi Efficacy and tolerability of fimasartan, a new angiotensin receptor blocker, compared with losartan (50/100 mg): a 12-week, phase III, multicenter, prospective, randomized, double-blind, parallel-group, dose escalation clinical trial with an optional 12-w
    Sang Eun Lee
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea
    Clin Ther 34:552-568, 568.e1-9. 2012
    ..Angiotensin receptor blockers (ARBs) is an effective and well tolerated first-line antihypertensive drug. Fimasartan is a newly developed ARB that has not been compared with other ARBs with regard to its efficacy and tolerability...
  39. ncbi Inhibition of diet-induced atherosclerosis and endothelial dysfunction in apolipoprotein E/angiotensin II type 1A receptor double-knockout mice
    Sven Wassmann
    Klinik fur Innere Medizin III, Universitatsklinikum des Saarlandes, Homburg Saar, Germany
    Circulation 110:3062-7. 2004
    ..Angiotensin II type 1 (AT1) receptor activation is potentially involved in the multifactorial pathogenesis of atherosclerosis...
  40. ncbi The Study on COgnition and Prognosis in the Elderly (SCOPE)--recent analyses
    Peter Trenkwalder
    Department of Internal Medicine, Starnberg Hospital, Ludwig Maximilian University Munich, Starnberg, Germany
    J Hypertens Suppl 24:S107-14. 2006
    ..Results in other subgroups were generally consistent with those in the entire SCOPE study population. In patients with slightly low cognitive function at baseline, the MMSE score declined less in the candesartan group...
  41. ncbi Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol
    Jeong Hyun Lee
    Department of Pharmacology, College of Medicine, Pusan National University, Busan, Korea
    J Pharmacol Exp Ther 313:502-9. 2005
    ....
  42. ncbi Dissociation of vasospasm and secondary effects of experimental subarachnoid hemorrhage by clazosentan
    Mohammed Sabri
    Division of Neurosurgery, St Michael s Hospital, University of Toronto, 30 Bond Street, Toronto, Ontario, Canada, M5B 1W8
    Stroke 42:1454-60. 2011
    ....
  43. ncbi Patient age and vasospasm after subarachnoid hemorrhage
    Mats Ryttlefors
    Department of Neuroscience, Section for Neurosurgery, Uppsala University Hospital, Uppsala, Sweden
    Neurosurgery 67:911-7. 2010
    ..Subarachnoid hemorrhage (SAH) from a ruptured intracranial aneurysm is a devastating disease with high mortality and morbidity. The incidence of SAH increases with advancing age...
  44. ncbi Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy
    Susumu Ogawa
    Division of Nephrology, Endocrinology and Vascular Medicine, Tohoku University School of Medicine, Sendai, Japan
    Hypertens Res 30:325-34. 2007
    ..Even among patients treated with an ACEI and/or ARB, lowering BP is important...
  45. ncbi The antihyperalgesic activity of a selective P2X7 receptor antagonist, A-839977, is lost in IL-1alphabeta knockout mice
    Prisca Honore
    Abbott Laboratories, Neuroscience Research, Abbott Park, IL 60064, USA
    Behav Brain Res 204:77-81. 2009
    ....
  46. pmc Effect of Renin-Angiotensin system blockade on insulin resistance and inflammatory parameters in patients with impaired glucose tolerance
    Stefan Pscherer
    Department of Nephrology and Diabetology, KlinikumTraunstein, Traunstein, Germany
    Diabetes Care 33:914-9. 2010
    ..The study investigated the effect of angiotensin receptor blockers (ARB) on glucose homeostasis and inflammatory parameters in patients with impaired glucose tolerance (IGT)...
  47. ncbi Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study
    Masayasu Matsumoto
    Department of Clinical Neuroscience and Therapeutics, Hiroshima University Graduate School of Biomedical Sciences, 1 2 3 Kasumi, Minami Ku, Hiroshima 734 8551, Japan
    Atheroscler Suppl 6:33-40. 2005
    ..These findings indicate that cilostazol may have a role as a vascular neuroprotectant, but the clinical implications are limited by the fact that patients were randomized to placebo instead of aspirin, which is the standard of care...
  48. ncbi A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazide
    Matthew R Weir
    University of Maryland School of Medicine, Baltimore, MD, USA
    J Clin Hypertens (Greenwich) 13:404-12. 2011
    ....
  49. pmc Secondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?
    James K Liao
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, 65 Landsdowne St, Rm 275, Cambridge, MA 02139, USA
    Circulation 115:1615-21. 2007
    ....
  50. pmc Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease
    Jun Wang
    Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Clin Invest 117:3393-402. 2007
    ..These preclinical studies suggest that certain antihypertensive drugs may have AD-modifying activity and may protect against progressive Abeta-related memory deficits in subjects with AD or in those at high risk of developing AD...
  51. ncbi Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program
    Akshay S Desai
    Department of Cardiology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Am Coll Cardiol 50:1959-66. 2007
    ..We explored the incidence and predictors of hyperkalemia in a broad population of heart failure patients...
  52. ncbi Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
    Stevo Julius
    University of Michigan, Ann Arbor, USA
    Lancet 363:2022-31. 2004
    ....
  53. ncbi Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries
    Wendy W Batenburg
    Department of Pharmacology, Erasmus MC, Rotterdam, The Netherlands
    Circulation 109:2296-301. 2004
    ..In contrast, AT2 receptor-mediated vasodilation could not be observed in large human coronary arteries. We studied Ang II-induced vasodilation of human coronary microarteries (HCMAs)...
  54. pmc Angiotensin AT2 receptors: cardiovascular hope or hype?
    Robert E Widdop
    Department of Pharmacology, Monash University, Melbourne, Victoria 3800, Australia
    Br J Pharmacol 140:809-24. 2003
  55. ncbi Cilostazol inhibits cytokine-induced nuclear factor-kappaB activation via AMP-activated protein kinase activation in vascular endothelial cells
    Yoshiyuki Hattori
    Department of Endocrinology and Metabolism, Dokkyo University School of Medicine, Mibu, Tochigi 321 0293, Japan
    Cardiovasc Res 81:133-9. 2009
    ..We hypothesized that cilostazol may prevent inflammatory cytokine induced-nuclear factor (NF)-kappaB activation by activating AMP-activated protein kinase (AMPK) in vascular endothelial cells...
  56. ncbi Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology
    Jennifer L Wilkinson-Berka
    Department of Immunology, Monash University, Commercial Rd, Prahran, Victoria, Australia, 3004
    Circ Res 104:124-33. 2009
    ..We make the first report that MR and aldosterone influence retinal vasculopathy, which may involve inflammatory and G6PD mechanisms. MR antagonism may be relevant when developing treatments for retinopathies that target the RAAS...
  57. ncbi PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin
    Ronald Clasen
    Center for Cardiovascular Research, Institut fur Pharmakologie und Toxikologie, Charite Campus Mitte, Charite Universitatsmedizin Berlin, Berlin, Germany
    Hypertension 46:137-43. 2005
    ..ARB-induced adiponectin stimulation is likely to be mediated via PPARgamma activation involving a post-transcriptional mechanism...
  58. ncbi Irbesartan in patients with atrial fibrillation
    Salim Yusuf
    Population Health Research Institute, McMaster University, Hamilton, ON, Canada
    N Engl J Med 364:928-38. 2011
    ..The risk of cardiovascular events among patients with atrial fibrillation is high. We evaluated whether irbesartan, an angiotensin-receptor blocker, would reduce this risk...
  59. ncbi Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats
    Maxim Krikov
    Center for Cardiovascular Research CCR Institute of Pharmacology, Charite Universitatsmedizin Berlin, Berlin, Germany
    J Hypertens 26:544-52. 2008
    ....
  60. ncbi A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial
    H G Beebe
    Jobst Vascular Center, Toledo, Ohio 43606, USA
    Arch Intern Med 159:2041-50. 1999
    ..Effective medication is limited for the relief of intermittent claudication, a common manifestation of arterial occlusive disease. Cilostazol is a potent inhibitor of platelet aggregation with vasodilation effects...
  61. ncbi Activation of endothelial nitric oxide synthase by cilostazol via a cAMP/protein kinase A- and phosphatidylinositol 3-kinase/Akt-dependent mechanism
    Ayako Hashimoto
    Research Institute of Pharmacological and Therapeutical Development, Otsuka Pharmaceutical Co Ltd, 463 10 Kagasuno, Kawauchi cho, Tokushima 771 0192, Japan
    Atherosclerosis 189:350-7. 2006
    ..These results suggest that cilostazol induces NO production by eNOS activation via a cAMP/PKA- and PI3K/Akt-dependent mechanism and that this effect is involved in capillary-like tube formation in HAEC...
  62. ncbi Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis
    Ken ichiro Okada
    Department of Internal Medicine and Therapeutics, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
    Circulation 110:705-12. 2004
    ..The ER responds to stress by upregulating ER chaperones, but prolonged and/or excess ER stress leads to apoptosis. However, the potential role of ER stress in pathophysiological hearts remains unclear...
  63. ncbi Irbesartan prevents metabolic syndrome in rats via activation of peroxisome proliferator-activated receptor γ
    Shinji Takai
    Department of Pharmacology, Osaka Medical College, Takatsuki, Osaka, Japan
    J Pharmacol Sci 116:309-15. 2011
    ..These findings suggest that through PPARγ stimulation along with angiotensin II inhibition, irbesartan may be an optimal treatment option in the prevention of metabolic syndrome as well as hypertension...
  64. ncbi Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial
    Steven G Chrysant
    Oklahoma Cardiovascular and Hypertension Center and the University of Oklahoma School of Medicine, 5850 W Wilshire Blvd, Oklahoma City, OK 73132, USA
    J Natl Med Assoc 101:300-7. 2009
    ..Fixed-dose irbesartan/HCTZ combination treatment provided effective and well-tolerated BP lowering in a diverse population of patients with isolated systolic hypertension...
  65. ncbi Effects of an N-type calcium antagonist on angiotensin II-renin feedback
    Shizuka Aritomi
    Pharmaceutical Research Laboratories, Ajinomoto Co, Inc, Kawasaki, Japan
    Am J Nephrol 33:168-75. 2011
    ....
  66. ncbi Beneficial effects of combination of valsartan and amlodipine on salt-induced brain injury in hypertensive rats
    Yi Fei Dong
    Department of Pharmacology and Molecular Therapeutics, Kumamoto University Graduate School of Medical Sciences, 1 1 1 Honjyo, Kumamoto 860 8556, Japan
    J Pharmacol Exp Ther 339:358-66. 2011
    ..Our results suggest that the combination of valsartan and amlodipine may be a promising strategy for the prevention of salt-related brain injury in hypertensive patients...
  67. ncbi Endothelial dysfunction and oxidative stress during estrogen deficiency in spontaneously hypertensive rats
    S Wassmann
    Medizinische Klinik und Poliklinik, Innere Medizin III, , Homburg/Saar, Germany
    Circulation 103:435-41. 2001
    ..Therefore, estrogen deficiency-induced AT(1) receptor overexpression and oxidative stress may play an important role in cardiovascular diseases associated with menopause...
  68. ncbi A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension
    Andrew J Palmer
    CORE Center for Outcomes Research, Allschwil Basel, Switzerland
    Curr Med Res Opin 22:2095-100. 2006
    ..We performed a cost-consequence analysis in a French setting of the renoprotective benefit of irbesartan in hypertensive type 2 diabetes patients over a 25-year period...
  69. ncbi Triple therapy with olmesartan medoxomil, amlodipine besylate, and hydrochlorothiazide in adult patients with hypertension: The TRINITY multicenter, randomized, double-blind, 12-week, parallel-group study
    Suzanne Oparil
    University of Alabama at Birmingham, 35294 0007, USA
    Clin Ther 32:1252-69. 2010
    ..Patients with hypertension may require a combination of > or =2 antihypertensive agents to achieve blood pressure (BP) control...
  70. ncbi Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats
    E J Henriksen
    Muscle Metabolism Laboratory, Department of Physiology, University of Arizona College of Medicine, Tucson, AZ, USA
    Hypertension 38:884-90. 2001
    ....
  71. ncbi Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland
    Andrew J Palmer
    Center for Outcomes Research CORE, Binningen Basel, Switzerland
    Swiss Med Wkly 136:346-52. 2006
    ....
  72. ncbi Comparison of amlodipine/valsartan fixed-dose combination therapy and conventional therapy
    Mark A Malesker
    Creighton University, School of Pharmacy and Health Professions, 2500 California Plaza, Omaha, NE 68178, USA
    Manag Care 19:36-42. 2010
    ....
  73. ncbi Early antihypertensive efficacy of olmesartan medoxomil
    Ikuo Saito
    Keio University Health Center, Tokyo, Japan
    J Clin Hypertens (Greenwich) 10:930-5. 2008
    ..3% at 2 weeks in the standard BP determination group (P=NS). Rates of adverse drug reactions in the 2 groups were similar. The present study suggests that OM is safe and effective in reducing BP at an early time point of treatment...
  74. ncbi The use of olmesartan medoxomil as monotherapy or in combination with other antihypertensive agents in elderly hypertensive patients in Japan
    Ikuo Saito
    Health Center, Keio University, Yokohama, Kanagawa, Japan
    J Clin Hypertens (Greenwich) 10:272-9. 2008
    ..Treatment was well tolerated in all groups. In conclusion, the medication was safe and effective in reducing BP levels in ISH patients aged 75 years and older, as well as in other elderly hypertensive patients...
  75. ncbi Comparison of real-world adherence, healthcare resource utilization and costs for newly initiated valsartan/amlodipine single-pill combination versus angiotensin receptor blocker/calcium channel blocker free-combination therapy
    Onur Baser
    The University of Michigan and STATinMED Research, Ann Arbor, MI 48104, USA
    J Med Econ 14:576-83. 2011
    ....
  76. ncbi Cilostazol inhibits oxidative stress-induced premature senescence via upregulation of Sirt1 in human endothelial cells
    Hidetaka Ota
    Department of Geriatric Medicine, Graduate School of Medicine, University of Tokyo, Japan
    Arterioscler Thromb Vasc Biol 28:1634-9. 2008
    ..The purpose of the present study was to clarify the molecular mechanisms underlying the preventive effect of treatment with cilostazol on oxidative stress-induced premature senescence in human endothelial cells...
  77. pmc The collecting duct is the major source of prorenin in diabetes
    Jung J Kang
    Department of Physiology, Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA
    Hypertension 51:1597-604. 2008
    ..These novel findings suggest that, in a rat model of diabetes, prorenin content and release from the CD may be more important than the juxtaglomerular apparatus in contrast to the existing paradigm...
  78. ncbi Efficacy and tolerability of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients not adequately controlled with valsartan monotherapy
    Jun Huang
    The First Affiliated Hospital with Nanjing Medical University, Nanjing, China
    Clin Exp Hypertens 33:179-86. 2011
    ..1-58.6%) monotherapies. The combination was well tolerated. In conclusion, single-pill combination with Aml/Val provided significant additional BP reduction and control in hypertensive patients not responding to Val 80 mg...
  79. ncbi Cardioprotective effects mediated by angiotensin II type 1 receptor blockade and enhancing angiotensin 1-7 in experimental heart failure in angiotensin-converting enzyme 2-null mice
    Vaibhav B Patel
    Division of Cardiology, Department of Medicine, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada
    Hypertension 59:1195-203. 2012
    ....
  80. ncbi Novel mechanism and role of angiotensin II induced vascular endothelial injury in hypertensive diastolic heart failure
    Eiichiro Yamamoto
    Department of Pharmacology and Molecular Therapeutics, Kumamoto University Graduate School of Medical Sciences, 1 1 1 Honjyo, Kumamoto 860 8556, Japan
    Arterioscler Thromb Vasc Biol 27:2569-75. 2007
    ..We examined the molecular mechanism of angiotensin (AII)-induced vascular endothelial injury and its significance for hypertensive diastolic heart failure...
  81. ncbi Efficacy and safety of a single-pill combination of amlodipine/valsartan in Asian hypertensive patients inadequately controlled with amlodipine monotherapy
    Yuannan Ke
    China Japan Friendship Hospital, Beijing, China
    Curr Med Res Opin 26:1705-13. 2010
    ..This multicentre, randomised, double-blind study assessed the efficacy and safety of a single-pill combination of amlodipine/valsartan versus amlodipine in Asian hypertensive patients...
  82. pmc Progress report on the first sub-Saharan Africa trial of newer versus older antihypertensive drugs in native black patients
    Augustine N Odili
    Studies Coordinating Centre, Division of Hypertension and Cardiovascular Rehabilitation, Department of Cardiovascular Diseases, University of Leuven Campus Sint Rafaël, Kapucijnenvoer 35, Block D, Box 7001, Leuven BE 3000, Belgium
    Trials 13:59. 2012
    ....
  83. ncbi Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study
    Ettore Malacco
    Department of Internal Medicine, Ospedale L Sacco, University of Milan, Milan, Italy
    J Hypertens 28:2342-50. 2010
    ..To compare the efficacy and safety of the angiotensin II antagonist olmesartan medoxomil (O) and the ACE inhibitor ramipril (R) in elderly patients with essential arterial hypertension...
  84. ncbi An Asian regional analysis of cost-effectiveness of early irbesartan treatment versus conventional antihypertensive, late amlodipine, and late irbesartan treatments in patients with type 2 diabetes, hypertension, and nephropathy
    Lieven Annemans
    Ghent University and IMS Health, Bruxelles, Belgium, and IMS Health, Bruxelles, Belgium
    Value Health 11:354-64. 2008
    ..This treatment has proven to be cost-effective in Western countries. This study assessed the cost-effectiveness of early irbesartan treatment in Asian settings...
  85. ncbi UVB radiation induces apoptosis in keratinocytes by activating a pathway linked to "BLT2-reactive oxygen species"
    Ho Cheol Ryu
    School of Life Sciences and Biotechnology, Korea University, Seoul, Korea
    J Invest Dermatol 130:1095-106. 2010
    ..Taken together, our results demonstrate that a "BLT2-Nox1"-linked pathway has a crucial role in UVB-induced ROS generation and mediates apoptosis in human keratinocytes...
  86. ncbi Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients
    Takeshi Takami
    Clinic Jinguumae, Kashihara, Japan
    Hypertens Res 26:609-14. 2003
    ....
  87. pmc Cilostazol activates function of bone marrow-derived endothelial progenitor cell for re-endothelialization in a carotid balloon injury model
    Rie Kawabe-Yako
    Group of Vascular Regeneration Research, Institute of Biomedical Research and Innovation, RIKEN Center for Developmental Biology, Kobe, Japan
    PLoS ONE 6:e24646. 2011
    ..We have investigated the hypothesis that CLZ might accelerate re-endothelialization with EPCs...
  88. ncbi Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both
    Marc A Pfeffer
    Cardiovascular Division, Brigham and Women s Hospital, Boston, MA 02115, USA
    N Engl J Med 349:1893-906. 2003
    ..In a double-blind trial, we compared the effect of the angiotensin-receptor blocker valsartan, the ACE inhibitor captopril, and the combination of the two on mortality in this population of patients...
  89. ncbi Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes
    Danilo Fliser
    Department of Internal Medicine, Medical School Hannover, Germany
    J Am Soc Nephrol 16:1135-40. 2005
    ..In addition, it significantly reduces oxidative stress. These effects of angiotensin II receptor antagonists may contribute to their beneficial long-term renal effects in patients with type 2 diabetes...
  90. ncbi Cilostazol increases tissue blood flow in contracting rabbit gastrocnemius muscle
    Miranda Fong
    Otsuka Maryland Medicinal Laboratories, Inc, Rockville, MD, USA
    Circ J 74:181-7. 2010
    ..In the present study the effect of cilostazol on blood flow and interstitial adenosine concentration was compared with that of the PDE3 inhibitor, milrinone, and the adenosine uptake inhibitor, draflazine...
  91. ncbi Clazosentan, an endothelin receptor antagonist, prevents early hypoperfusion during the acute phase of massive experimental subarachnoid hemorrhage: a laser Doppler flowmetry study in rats
    Gerrit A Schubert
    Department of Neurosurgery, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany
    J Neurosurg 109:1134-40. 2008
    ..The purpose of this study was to further determine the role of ET in the first minutes to hours after massive experimental SAH induced by prophylactic treatment with the ET receptor antagonist clazosentan...
  92. pmc Biomedical applications of tetrazine cycloadditions
    Neal K Devaraj
    Center for Systems Biology, Massachusetts General Hospital, 185 Cambridge Street, CPZN 5206, Boston, Massachusetts 02114, USA
    Acc Chem Res 44:816-27. 2011
    ..Future work with tetrazine cycloadditions will undoubtedly lead to optimized protocols, improved probes, and additional biomedical applications...
  93. ncbi Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension
    Martin Busch
    Department of Internal Medicine III, University of Jena, Jena, Germany
    Nephron Clin Pract 108:c291-7. 2008
    ....
  94. ncbi Pharmacotherapy for peripheral arterial disease: emerging therapeutic options
    Michael R Jaff
    The Vascular Ultrasound Core Laboratory, Morristown NJ 07960, USA
    Angiology 53:627-33. 2002
    ..Revascularization procedures, including nonsurgical and surgical techniques, can thus be reserved to improve patency and reduce the risk of limb loss in patients with PAD and IC with more severe impairment...
  95. ncbi The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients
    R Negro
    Department of Endocrinology, AUSL LE 1, P O V Fazzi, Piazza F Muratore, 73100, Lecce, Italy
    J Endocrinol Invest 29:957-61. 2006
    ....
  96. ncbi An AT1-receptor antagonist and an angiotensin-converting enzyme inhibitor protect against hypoxia-induced apoptosis in human aortic endothelial cells through upregulation of endothelial cell nitric oxide synthase activity
    Naoyuki Matsumoto
    First Department of Internal Medicine, Kyoto Prefectural University of Medicine, Kawaramachi Hirokoji, Kamigyo ku, Kyoto, 602 0841, Japan
    Shock 19:547-52. 2003
    ..Both CS and TC can ameliorate hypoxia-induced apoptosis in HAEC through inhibiting caspase-3 activation by enhancing ecNOS activity, via the accumulation of BK...
  97. pmc Effects of Azelnidipine plus OlmesaRTAn versus amlodipine plus olmesartan on central blood pressure and left ventricular mass index: the AORTA study
    Takeshi Takami
    Department of Internal Medicine, Clinic Jingumae, Kashihara, Japan
    Vasc Health Risk Manag 7:383-90. 2011
    ..The aim of this study was to compare the effects of olmesartan combined with either azelnidipine or amlodipine on central blood pressure (CBP) and left ventricular mass index (LVMI) in hypertensive patients...
  98. pmc Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records
    Yayoi Nishida
    Division of Genomic Epidemiology and Clinical Trials, Advanced Medical Research Center, Nihon University School of Medicine, 30 1 Oyaguchi Kamimachi, Itabashi ku, Tokyo 173 8610, Japan
    Cardiovasc Diabetol 9:38. 2010
    ..Our aims were to survey the changes in plasma lipid profile in patients with hypertension over a one-year period, and to examine the correlations between these values and the time after the start of ARB monotherapy with candesartan...
  99. pmc 24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertension
    Y Lacourciere
    Hypertension Research Unit, Centre Hospitalier Universitaire de Quebec, Quebec, Canada
    J Hum Hypertens 25:615-22. 2011
    ..Once-daily treatment with amlodipine/valsartan/hydrochlorothiazide (10/320/25 mg) reduces ABP to a significantly greater extent than component-based dual therapy and maintains its effectiveness over the entire 24-h dosing period...
  100. ncbi Cilostazol in the management of atherosclerosis
    Fabrizio Sallustio
    Department of Neuroscience, Stroke Unit, University of Tor Vergata, 00133 Rome, Italy
    Curr Vasc Pharmacol 8:363-72. 2010
    ..This review will focus on the pharmacological properties of cilostazol and its use in the management of atherothrombotic vascular diseases...
  101. ncbi Rationale and design of the Newer Versus Older Antihypertensive Agents in African Hypertensive Patients (NOAAH) trial
    Augustine N Odili
    Studies Coordinating Centre, Division of Hypertension and Cardiovascular Rehabilitation, Department of Cardiovascular Diseases, University of Leuven, Leuven, Belgium
    Blood Press 20:256-66. 2011
    ....

Research Grants63

  1. Chemical Probes Targeting the Protein Arginine Deiminases
    Paul R Thompson; Fiscal Year: 2013
    ..the backbone amides in Cl-amidine, an inhibitor developed by the PI's lab, with libraries of triazoles and tetrazoles;and (i) a cyclic peptoid library approach...
  2. Development and Applications of Photoinducible Bioorthogonal Chemistry
    Qing Lin; Fiscal Year: 2013
    ..we propose to significantly expand the scope and the utility of this reaction toolbox by: 1) identifying tetrazoles with enhanced reactivity toward unactivated alkenes;2) developing a photoinducible diarylazirine-based ..
  3. Novel agents against West Nile Virus infections
    Krzysztof Pankiewicz; Fiscal Year: 2003
    ..The use of tetrazoles in medicinal chemistry is growing fast since these compounds are well transported into cells and often show ..
  4. Peptidomimetics of D-Ala-D-Ala as Novel Antibacterials
    Norma Dunlap; Fiscal Year: 2003
    ..Linear analogs of D-ala-D-ala containing a carboxylic acid will be synthesized, as will cyclopropyl analogs. Tetrazoles have been used successfully as bioisosteric replacements for the carboxylic acids in a number of drugs...
  5. Oxidative Stress and Genetics of Prehypertension
    Shawna Nesbitt; Fiscal Year: 2004
    ..abstract_text> ..
  6. MODERATE ALCOHOL USE--CARDIOVASCULAR RISKS AND BENEFITS
    Thomas Giles; Fiscal Year: 2001
    ..The exacerbation or prevention of EIH will be related to drug effects on the cell-signaling pathway. This research can define the cell-signaling pathway in EIH and provide new and novel approaches to treating EIH. ..
  7. ADVENTITIAL RESPONSE TO VASCULAR INJURY: ESTROGEN
    Suzanne Oparil; Fiscal Year: 2003
    ..These fundamental mechanistic studies will establish more rational strategies for therapeutic intervention in vascular diseases, including the basis for future gene therapy. ..
  8. Estrogen Modulates Injury-Induced Inflammation
    Suzanne Oparil; Fiscal Year: 2007
    ..These fundamental mechanistic studies will enhance our understanding of the pathobiology of vascular disease, particularly as it occurs in aging women, and will provide the basis for development of novel therapeutic strategies. ..
  9. ANG II AND IGF-1 INTERACTION IN CARDIOVASCULAR TISSUE
    James Sowers; Fiscal Year: 2003
    ..Thus, the proposed investigation will explore the role of PI3-kinase in mediating the cardiovascular interactions of AngII/IGF-1 after both short-term in vitro Ang II exposure and longer-term in vivo Ang II tissue excess. ..
  10. Angiotensin II Mediates Early Changes in Diabetic Kidney
    Helmy Siragy; Fiscal Year: 2007
    ..The proposed studies will help understand the mechanisms that are involved in diabetic the development of new therapeutic modalities to prevent or slowdown the development ..
  11. AT2 Receptor Modulates Renal Angiotensin II Levels
    Helmy Siragy; Fiscal Year: 2005
    ..Data obtained from this proposal will lead to increased understanding of the pathophysiology of hypertension and development of novel therapies for its management. ..
  12. Lipoproteins, HIV, and Antiretroviral Therapy in SMART
    Daniel Duprez; Fiscal Year: 2008
    ..This proposal will produce additional information that will enhance their disease-free survival rate. (End of Abstract) [unreadable] [unreadable] [unreadable]..
  13. Mechanisms of ATP Release from RBC's
    Randy Sprague; Fiscal Year: 2007
    ..abstract_text> ..
  14. PATHOPHYSIOLOGY OF CHRONIC CEREBRAL VASOSPASM
    Robert MacDonald; Fiscal Year: 2005
    ..abstract_text> ..
  15. HIGH RESOLUTION ECHOCARDIOGRAPHY SYSTEM
    Michael Zile; Fiscal Year: 2001
    ..This will foster interdisciplinary investigation, support NIH-funded investigators and trainees, and enhance the competitiveness of MUSC investigators. ..
  16. ATHEROGENESIS AND THE BONE MARROW ANGIOTENSIN SYSTEM
    Carlos Ferrario; Fiscal Year: 2004
    ..The proposed research will uncover novel mechanisms of atherogenesis that may have significant impact in the development of new therapeutic modalities applicable to cardiovascular and blood vessel diseases. ..
  17. Role of Erythrocytes in Circulatory Control
    Randy Sprague; Fiscal Year: 2004
    ..abstract_text> ..
  18. "MENTORED PATIENT-ORIENTED RESEARCH CAREER DEVELOPMENT AWARD"
    Allon Friedman; Fiscal Year: 2009
    ..abstract_text> ..
  19. Control of Conjuctival Goblet Cell Mucin Production
    Darlene Dartt; Fiscal Year: 2009
    ..Study of the signaling pathways that stimulate conjunctival goblet cell proliferation will lead to the development of treatments to replenish the mucin layer in these diseases. ..
  20. Establishing the Precursors of Osteoporosis in Children
    Xiping Xu; Fiscal Year: 2010
    ....
  21. Role of PI3-Kinase in Estrogen-induced eNOS Activation
    James Liao; Fiscal Year: 2007
    ..These results may explain some of the actions of selective estrogen receptor modulators (SERMs) and provide a therapeutic basis for using estrogens in cardiovascular disease. ..
  22. A Randomized, Controlled Pilot Study of an Intervention for Medication Adherence
    Bradi B Granger; Fiscal Year: 2010
    ..Although medication adherence improves CHF outcomes, adherence rates remain around 50%. The intervention to be tested in these projects has the potential to improve CHF outcomes by improving adherence rates. ..
  23. Antipsychotic Actions in Models of NMDA Hypofunction
    Gary Duncan; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  24. Air Pollution Exposure/Atherosclerosis:Vascular Mechanism
    Sanjay Rajagopalan; Fiscal Year: 2007
    ..This study is expected to provide a firm linkage between CAPS exposure and atherosclerosis progression and will provide a pathophysiologic basis for the adverse cardiovascular effects of CAPS. ..
  25. Neural Mechanism of Thiazide-Induced Insulin Resistance
    Wanpen Vongpatanasin; Fiscal Year: 2008
    ....
  26. Genetics of Chronic Kidney Disease
    Stephen T Turner; Fiscal Year: 2010
    ..abstract_text> ..
  27. Oxidative Stress and Myocardial Remodeling Following MI
    Yao Sun; Fiscal Year: 2008
    ..abstract_text> ..
  28. The 7th International Conference on Head and Neck Cancer
    Jeffrey Myers; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  29. Air Pollution and Hypertension: Vascular Mechanisms
    Sanjay Rajagopalan; Fiscal Year: 2010
    ..5 exposure. These insights may lead to future testable methods potentially capable of reducing the tremendous public health burden of PM2.5. ..
  30. Arterial 5-HT Transporter Function
    Stephanie Watts; Fiscal Year: 2009
    ..abstract_text> ..
  31. Endothelial Akt in Vascular Injury
    James Liao; Fiscal Year: 2009
    ..Three specific aims are proposed, which will study the role of endothelial Akt in models of vascular injury and atherosclerosis. ..
  32. TRPV1 Expressing Sensory Afferents in Postoperative Pain
    Timothy Brennan; Fiscal Year: 2009
    ..A separate pathway, likely an A-fiber mediated pathway, is sufficient to transmit the enhanced mechanical responses. ..
  33. THROMBOTIC, INFLAMMATORY & GENE MARKERS OF CVD IN WOMEN
    Paul Ridker; Fiscal Year: 2002
    ....
  34. Intrarenal Augmentation of Angiotensinogen by Ang II
    Hiroyuki Kobori; Fiscal Year: 2010
    ..abstract_text> ..
  35. AASK Cohort Study
    George Bakris; Fiscal Year: 2007
    ..Such results might eventually lead to new strategies that delay or prevent ESRD. ..
  36. TNF-alpha Underlies Glomerular Aging in B6 Females
    Feng Zheng; Fiscal Year: 2010
    ..This proposal will attempt to identify factor(s) contributing to the development and progression of glomerulosclerosis in aging. ..
  37. POSITIONAL CANDIDATE GENE APPROACHES IN ASTHMA GENE DISC
    Xiping Xu; Fiscal Year: 2006
    ..The findings from the proposed study may lead to improved strategies for prevention, diagnosis, and treatment of this disease. (End of Abstract.) ..
  38. GENETIC EPIDIMOLOGY OF OSTEOPOROSIS
    Xiping Xu; Fiscal Year: 2005
    ..OS (Osteoporosis in Men) studies. ..
  39. Robotics Extraction System/HPLC for Shared Resource Lab
    Mark Chappell; Fiscal Year: 2005
    ..abstract_text> ..
  40. Folic Acid Intake and Risk of Hypertension
    John Forman; Fiscal Year: 2004
    ..Subsequently, the risk of hypertension will be analyzed in > 2000 men and women genotyped for eNOS, and > 7000 men and women genotyped for MTHFR. Interaction with folate will be analyzed. ..
  41. ORGANOPHOSPHATE PESTICIDES AND HUMAN REPRODUCTIVE HEALTH
    Xiping Xu; Fiscal Year: 2003
    ..S.; and (9) the population possesses unique characteristics for examining the proposed hypothesis, i.e., a stable workforce, a non-smoking group and excellent compliance rates. ..
  42. ANGIOTENSIN II AND MITOGEN ACTIVATED PROTEIN KINASE
    Willa Hsueh; Fiscal Year: 2003
    ..5) Investigate the mechanism of transcription at regulation of PAI-1 by hyperglycemia AngII, insulin and the MAPK inhibitor in cultured rat cardiac fibroblasts. ..
  43. Nitric Oxide and Cardiac Remodeling Following Infarction
    Yao Sun; Fiscal Year: 2003
    ....
  44. NATURAL PRODUCT SYNTHESIS THROUGH TEMPLATE DIRECTED C-H
    DUNCAN WARDROP; Fiscal Year: 2003
    ..abstract_text> ..
  45. SECONDARY PREVENTION TRIAL OF VENOUS THROMBOSIS
    Paul Ridker; Fiscal Year: 2002
    ....
  46. PPARGAMMA AND AII IN GLOMERULOSCLEROSIS
    Willa Hsueh; Fiscal Year: 2002
    ..abstract_text> ..
  47. GENETICS OF HYPERTENSION AND ITS INTERMEDIATE PHENOTYPES
    Xiping Xu; Fiscal Year: 2001
    ..Thus, the genetic factors contributing to hypertension in this population may be less heterogeneous and more readily detected. ..
  48. SOFTWARE EFFECT ON PROMOTING ADHERENCE TO CHF GUIDELINES
    Lawrence Baruch; Fiscal Year: 2005
    ..If this decision support system is successful and widely implemented, the best outcomes from care for chronic heart failure may be achieved. ..
  49. Black Pooling Project
    Daniel Lackland; Fiscal Year: 2005
    ..We will also examine the multivariate risk functions in blacks and whites in the three contexts: ordering risk, magnitude of relative risks, and estimation of absolute risk. ..
  50. CYP2J2 Derived Eicosanoids and Endothelial Function
    Craig Lee; Fiscal Year: 2005
    ..abstract_text> ..
  51. GABA Receptors in the Acquisition and Extinction of Fear
    Scott Heldt; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  52. Anthipertensive PharmacoGenomics
    Stephen Turner; Fiscal Year: 2006
    ..abstract_text> ..
  53. Heart Failure and Beta-Blocker Use in Older Adults
    Ali Ahmed; Fiscal Year: 2006
    ..abstract_text> ..
  54. Synthesis through N-Acylnitrenium Ion Cyclization
    DUNCAN WARDROP; Fiscal Year: 2006
    ..abstract_text> ..
  55. CHEMICAL INDUCED NEPHROTOXICITY--SUCCINIMIDES
    GARY RANKIN; Fiscal Year: 2001
    ..Collectively, the results of these studies should add important, new knowledge about the nephrotoxic and urotoxic species of succinimides, cellular targets of the toxicant species and potential mechanisms of nephrotoxicity. ..
  56. POSTMENOPAUSAL HORMONAL REPLACEMENT THERAPY
    Wanpen Vongpatanasin; Fiscal Year: 2006
    ..The long-term goal of her work would be the discovery the most effective estrogen preparation that can prevent or treat hypertension in women after menopause. ..
  57. GENETIC EPIDEMIOLOGY OF RESPONSES TO ANTIHYPERTENSIVES
    Stephen Turner; Fiscal Year: 2006
    ....
  58. KIDNEY RESPONSE TO RADIATION AND CHEMOTHERAPY
    JOHN MOULDER; Fiscal Year: 2006
    ..unreadable] 4) Complete the randomized, prospective, trial of the use of ACE inhibitors to prevent the development of radiation nephropathy in BMT patients. [unreadable] [unreadable]..
  59. AUTOMATED CARDIAC DECISION SUPPORT SYSTEM IMPROVES CARE
    Lawrence Baruch; Fiscal Year: 2005
    ..If this automated clinical information and decision support system is successful and widely implemented, the best outcomes from care for chronic cardiovascular disease may be achieved. ..
  60. A central aortic pulse wave velocity measurement device
    Gary Mitchell; Fiscal Year: 2005
    ..This innovative technology will enable accurate diagnosis and risk stratification in a primary care setting and will facilitate further research aimed at evaluating interventions that may reduce conduit vessel stiffness. ..
  61. ESCAPE Mechanistic Substudies
    Robert Califf; Fiscal Year: 2003
    ..Catecholamines are also being collected at baseline and 3 months. In addition, the ESCAPE investigators are all ready capturing detailed demographic, clinical, and physiological information as part of the protocol for the primary study. ..
  62. REGULATION OF RENAL FUNCTION AND BP BY THROMBOXANE
    CHRISTOPHER WILCOX; Fiscal Year: 2002
    ....